Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Chelidonic acid

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-P0667

  • Specification : 95.0%(HPLC)

  • CAS number : 99-32-1

  • Formula : C7H4O6

  • Molecular Weight : 184.103

  • PUBCHEM ID : 7431

  • Volume : 50mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0667

Analysis Method

HPLC,NMR,MS

Specification

95.0%(HPLC)

Storage

2-8°C

Molecular Weight

184.103

Appearance

Powder

Botanical Source

Structure Type

Miscellaneous

Category

SMILES

C1=C(OC(=CC1=O)C(=O)O)C(=O)O

Synonyms

4-oxopyran-2,6-dicarboxylic acid

IUPAC Name

4-oxopyran-2,6-dicarboxylic acid

Applications

Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test. PUMID/DOI:27037280 Exp Biol Med (Maywood). 2016 Aug;241(14):1559-67. Depression is usually accompanied by neuro-inflammatory reactions. Chelidonic acid, in particular, has shown anti-inflammatory effects. The objective of this study was to evaluate the anti-depressant effects of Chelidonic acid and to discuss the potential mechanisms of a forced swimming test. Chelidonic acid was administered orally once a day for 14 days. On the 14th day, Chelidonic acid resulted in a significant decrease in immobility time during the forced swimming test without alteration of locomotor activity, in an open field test. In addition, Chelidonic acid significantly increased the levels of 5-hydroxytryptamine (serotonin), dopamine, and norepinephrine compared with those levels for the mice that were administered distilled water in the hippocampus. These results suggest that Chelidonic acid might serve as a new therapeutic strategy for the regulation of depression associated with inflammation. Effects of chelidonic acid, a secondary plant metabolite, on mast cell degranulation and adaptive immunity in rats. PUMID/DOI:27620504 Int Immunopharmacol. 2016 Nov;40:229-234. The present study evaluated the immunomodulatory effects of Chelidonic acid, a secondary plant metabolite, with therapeutic potential in allergic disorders, in experimental animals. In mast cell degranulation studies, ovalbumin immunized and challenged rats, Chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with vehicle treated group, and these effects were comparable with prednisolone (10mg/kg). A reduction in post-challenge mortality was also observed in all treated groups. Further, there were reductions in the blood eosinophil counts and serum IgE levels after Chelidonic acid treatment. Chelidonic acid also inhibited histamine release from rat peritoneal mast cells (RPMC) in vitro, in a dose related manner. In tests for adaptive immunity, in rats immunized with sheep RBC, Chelidonic acid differentially suppressed the (a) plaque forming cell (PFC) count in rat splenic cells, (b) anti-SRBC antibody titre and serum IgG levels and (c) increases in foot pad thickness in the DTH assay - all of which were comparable with prednisolone. These experimental results are discussed in light of the possible therapeutic potential of Chelidonic acid in allergic disorders.

Density

1.821 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

204.1ºC

Boiling Point

471.3ºC at 760 mmHg

Melting Point

265 °C (dec.)(lit.)

InChl

InChI=1S/C7H4O6/c8-3-1-4(6(9)10)13-5(2-3)7(11)12/h1-2H,(H,9,10)(H,11,12)

InChl Key

PBAYDYUZOSNJGU-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2932990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:99-32-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31100934

Abstract

4-oxo-4H-pyran-2.6-dicarboxylic acid (chelidonic acid, ChA) in the native state and in the complex with calcium [Ca(ChA)(H2O)3], named saucalchelin (CaChA), was isolated from the extract of Saussurea controversa leaves for the first time for the Asteraceae family. The structure of ChA was determined by NMR, MS and confirmed by X-ray analysis of its monomethyl ester, and CaChA was described by IR, ICP-MS, CHN analysis. The yield of ChA and CaChA was 45 mg/g and 70 mg/g of extract, respectively. The osteogenic activity of ChA, n-monobutyl ester of chelidonic acid, and CaChA has been studied in vitro in a 21-day culture of human adipose-derived multipotent mesenchymal stromal cells (hAMMSCs) in a standard nutrient medium without osteogenic supplements. CaChA significantly stimulated the growth of cell mass and differentiation of hAMMSCs into osteoblasts with subsequent mineralization of the culture and it may be a promising substance for accelerating bone tissue regeneration and engineering.

KEYWORDS

4-oxo-4H-pyran-2.6-dicarboxylic acid esters; Saussurea controversa DC (Asteraceae); X-ray diffraction analysis; chelidonic acid; human multipotent mesenchymal stromal cells.

Title

Chelidonic Acid and Its Derivatives from Saussurea Controversa: Isolation, Structural Elucidation and Influence on the Osteogenic Differentiation of Multipotent Mesenchymal Stromal Cells In Vitro

Author

Elena Avdeeva 1, Elvira Shults 2 3, Tatyana Rybalova 4 5, Yaroslav Reshetov 6, Ekaterina Porokhova 7, Irina Sukhodolo 8, Larisa Litvinova 9, Valeria Shupletsova 10, Olga Khaziakhmatova 11, Igor Khlusov 12 13, Artem Guryev 14, Mikhail Belousov 15 16

Publish date

2019 May 16

PMID

30086816

Abstract

Background: Oxyclozanide (OXY) is a veterinary medicine used for control of fascioliasis in farm animals. Literature review shows absence of sufficient information regarding its stability. Such information is important as it affects many stages of a drug’s life cycle, from pharmaceutical manufacturing to its environmental fate understanding of the degradation of the drug once it is placed in the environment. Objective: An HPLC method was developed to address the impact of different stress conditions on OXY’s stability. Methods: OXY’s stability was investigated by exposure to forced acid and alkaline hydrolysis, thermal, oxidative and photolytic degradation, which are different stress conditions applied to the forced degradation study. Separation was performed on Eurosphere C18 analytical column (125 × 4.6 mm, 5 μm particle size) using 50 mM sodium acetate trihydrate (pH 4.5) and acetonitrile (50:50, v/v) as mobile phase and UV detection at 254 nm. A photolytic kinetics study was conducted by monitoring OXY photolysis under monochromatic and polychromatic light sources (UV lamp at 366 nm and natural sunlight) in aqueous buffers of different pHs (5, 7, and 9). LC-MS was used to identify the major photolytic degradate. Results: OXY was quantified over a concentration range of 1-80 μg/mL with mean recovery of 99.32 ± 1.80%. The drug was susceptible to oxidative and photolytic degradation. The photolytic kinetics were pH dependent. The LC-MS result supported photo-dehalogenation degradation mechanism. Conclusions: The developed method could be used in OXY stability testing. The results of the photolytic kinetics study can address OXY aquatic photo-transformation, thereby predicting its environmental fate and risks imposed on the ecosystem. Highlights: An HPLC method was developed for monitoring OXY degradation behavior and studying its photolytic kinetics with identification of its photodegradate.

Title

Study of Oxyclozanide's Innate Stability Coupled with the Assessment of its Aquatic Photo-Transformation Using a Validated Isocratic HPLC Method

Author

Ahmed S Saad 1, Nahla S Ismail 2, Marwa Soliman 2, Hala E Zaazaa 1

Publish date

2019 Mar 1;

PMID

27620504

Abstract

The present study evaluated the immunomodulatory effects of chelidonic acid, a secondary plant metabolite, with therapeutic potential in allergic disorders, in experimental animals. In mast cell degranulation studies, ovalbumin immunized and challenged rats, chelidonic acid (1, 3 and 10mg/kg, i.p.) dose relatedly prevented ovalbumin challenge induced mast cell degranulation by differing degrees when compared with vehicle treated group, and these effects were comparable with prednisolone (10mg/kg). A reduction in post-challenge mortality was also observed in all treated groups. Further, there were reductions in the blood eosinophil counts and serum IgE levels after chelidonic acid treatment. Chelidonic acid also inhibited histamine release from rat peritoneal mast cells (RPMC) in vitro, in a dose related manner. In tests for adaptive immunity, in rats immunized with sheep RBC, chelidonic acid differentially suppressed the (a) plaque forming cell (PFC) count in rat splenic cells, (b) anti-SRBC antibody titre and serum IgG levels and (c) increases in foot pad thickness in the DTH assay – all of which were comparable with prednisolone. These experimental results are discussed in light of the possible therapeutic potential of chelidonic acid in allergic disorders.

KEYWORDS

Allergic disorders; Cell mediated immunity; Chelidonic acid; Humoral immunity; Mast cell degranulation.

Title

Effects of chelidonic acid, a secondary plant metabolite, on mast cell degranulation and adaptive immunity in rats

Author

Dhirendra Kumar Singh 1, Kavita Gulati 1, Arunabha Ray 2

Publish date

2016 Nov